X4 Pharmaceuticals drops 5%, prices $135M equity

* X4 Pharmaceuticals (NASDAQ:XFOR [https://seekingalpha.com/symbol/XFOR]) priced [https://seekingalpha.com/pr/20278619-x4-pharmaceuticals-announces-pricing-of-135-million-underwritten-public-offering] its previously announced underwritten public offering of 45.86M shares at $2.90 and warrants to purchase up to 700K shares at a public offering price of $2.899 per pre-funded warrant.
* The aggregate gross proceeds to X4 are expected to be ~$135M.
* The offering is expected to close on October 27, 2025.
* The underwriters have an option for a period of 30 days to purchase up to an additional ~6.98M shares.
* Net proceeds, together with its existing cash and cash equivalents and cash flows from operations, will be used to fund the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders, as well as for general and administrative expenses, capital expenditures, working capital and other general corporate purposes.
* The stock price dropped 5.2% on Thursday during after-market hours of trading.

MORE ON X4 PHARMACEUTICALS

* X4 Pharmaceuticals announces proposed underwritten public offering [https://seekingalpha.com/news/4507837-x4-pharmaceuticals-announces-proposed-underwritten-public-offering]
* X4 Pharmaceuticals to reduce 50% of workforce [https://seekingalpha.com/news/4495604-x4-pharmaceuticals-to-reduce-50-of-workforce]
* Seeking Alpha’s Quant Rating on X4 Pharmaceuticals [https://seekingalpha.com/symbol/XFOR/ratings/quant-ratings]
* Historical earnings data for X4 Pharmaceuticals [https://seekingalpha.com/symbol/XFOR/earnings]
* Financial information for X4 Pharmaceuticals [https://seekingalpha.com/symbol/XFOR/income-statement]